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ABSTRACT 1 
Purpose: Acute acetaminophen (ACT) ingestion has been shown to enhance cycling time-2 
trial performance.  The purpose of this study was to assess whether ACT ingestion enhances 3 
muscle activation and critical power (CP) during maximal cycling exercise. Methods: 4 
Sixteen active male participants completed two 3-min all-out tests against a fixed resistance 5 
on an electronically-braked cycle ergometer 60 minutes following ingestion of 1 g ACT or 6 
placebo (maltodextrin, PL). CP was estimated as the mean power output over the final 30 s of 7 
the test and W′ (the curvature constant of the power-duration relationship) was estimated as 8 
the work done above CP. The femoral nerve was stimulated every 30 s to measure membrane 9 
excitability (M-wave) and surface electromyography (EMGRMS) was recorded continuously 10 
to infer muscle activation. Results: Compared to PL, ACT ingestion increased CP (ACT: 297 11 
± 32 vs PL: 288 ± 31 W, P<0.001) and total work done (ACT: 66.4 ± 6.5 vs PL: 65.4 ± 6.4 12 
kJ, P=0.03) without impacting Wˈ (ACT: 13.1 ± 2.9 vs PL: 13.6 ± 2.4 kJ, P=0.19) or the M-13 
wave amplitude (P=0.66) during the 3-min all-out cycling test. Normalized EMGRMS 14 
amplitude declined throughout the 3-min protocol in both PL and ACT conditions; however, 15 
the decline in EMGRMS was attenuated in the ACT condition, with the EMGRMS amplitude 16 
being greater compared to PL over the last 60 s of the test (P=0.04). Conclusion: These 17 
findings indicate that acute ACT ingestion might increase performance and CP during 18 
maximal cycling exercise by enhancing muscle activation. 19 
 20 
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INTRODUCTION 23 
Fatigue is a complex, multi-factorial process that is linked to perturbations within the central 24 
nervous system and the contracting skeletal muscles (Enoka & Duchateau, 2008; Hureau et 25 
al. 2016). Recent studies suggest that fatigue development may be related, at least in part, to 26 
pain sensation (Astokorki & Mauger 2017a; Astokorki & Mauger 2017b; O’Leary et al. 27 
2017). Acetaminophen (ACT) is a commonly used medicine for general pain relief.  28 
Ingestion of ACT lowers pain sensation through inhibiting the cyclooxygenase enzymes, 29 
which stimulate nociceptor discharge through the synthesis of prostaglandins (Graham et al. 30 
2013; Jóźwiak-Bębenista & Nowak, 2014), and modulating serotoninergic, opioid and 31 
cannabinoid pathways (Graham et al. 2013; Pickering et al. 2006, 2008). Acute ACT 32 
ingestion has been shown to enhance endurance exercise performance consistent with the 33 
notion that interventions which can modulate pain sensation have the potential to influence 34 
exercise performance (Foster et al. 2014; Mauger et al. 2010, Morgan et al. 2018). Indeed, 35 
similar to the effects of caffeine (O’Connor et al. 2004), Mauger et al. (2010) and Foster et al. 36 
(2014) have both previously reported enhanced exercise performance and/or work output at a 37 
given level of muscle pain following acute ACT ingestion. These results suggest that ACT 38 
reduces pain at a given absolute work rate and/or permits a higher work rate for an equivalent 39 
pain sensation.  40 
 41 
In a recent study, Morgan et al. (2018) reported an attenuated decline in skeletal muscle 42 
electromyography (EMG) amplitude, reflective of an increase in muscle activation, and an 43 
increased critical torque during a maximal intermittent single-leg knee extensor test following 44 
ACT ingestion. During cycling exercise, the power equivalent of the critical torque, the 45 
critical power (CP), represents an important threshold for oxidative metabolic control and 46 
exercise tolerance (Jones et al. 2010; Vanhatalo et al. 2011). Indeed, CP, which is the 47 
 
 
asymptote of the hyperbolic relationship between power output and time to exhaustion, 48 
reflects the highest work rate that can be sustained without a progressive loss of 49 
intramuscular and systemic homeostasis (Black et al. 2016; Poole et al. 1988; Poole et al. 50 
1990; Vanhatalo et al. 2016), and interacts with the curvature constant of this relationship, 51 
W′, to define exercise tolerance within the severe exercise intensity domain (Jones et al. 52 
2010; Vanhatalo et al. 2011). Since CP is linked to muscle activation and neuromuscular 53 
fatigue development during exercise, as inferred from EMG responses (Burnley et al. 2012), 54 
and since ACT ingestion can concomitantly influence EMG responses and the critical torque 55 
(Morgan et al., 2018), ACT might also enhance CP by modulating aspects of central fatigue 56 
development during large muscle mass exercise. This potential blunting in central fatigue 57 
development could be mediated by inhibition of nociceptor sensitising prostaglandins 58 
(Graham et al. 2013; Jóźwiak-Bębenista & Nowak, 2014) and/or enhanced corticospinal 59 
excitability (Mauger & Hopker, 2013) permitting an increased CP and thus improved 60 
endurance exercise performance.      61 
 62 
Although the improvement in cycling performance that has been reported following ACT 63 
ingestion (Foster et al. 2014; Mauger et al. 2010) may also be linked to enhanced 64 
neuromuscular function and a higher CP, as observed during single leg exercise (Morgan et 65 
al. 2018), the exercise modality and the volume of skeletal muscle mass engaged are known 66 
to influence the degree of neuromuscular and peripheral fatigue development. Specifically, 67 
greater peripheral fatigue development has been observed at the same relative intensity 68 
during knee-extensor exercise compared to cycling exercise (Rossman et al. 2012, 2014).  69 
Therefore, the mechanisms underpinning the potential ergogenic effect of ACT on larger 70 
muscle mass exercise such as cycling, which is more relevant for sports performance, 71 
requires further research.  72 
 
 
 73 
The purpose of the present study was, therefore, to assess the effect of acute ACT ingestion 74 
on neuromuscular fatigue development and its potential underlying mechanisms during large 75 
muscle mass exercise. We tested the hypotheses that, compared to placebo, acute 76 
consumption of 1 g ACT would increase total work done, CP and muscle activation during a 77 
3-min all-out cycling test. 78 
 79 
MATERIALS AND METHODS 80 
Participants 81 
Sixteen trained male cyclists (mean ± SD: age 29 ± 9 y, height 1.79 ± 0.07 m, body mass 77 82 
± 8 kg, V̇O2peak 60.8 ± 7.0 ml·kg-1·min-1, range: 52-77 ml·kg-1·min-1) provided written 83 
informed consent to participate in the present study, which was approved by the local Ethics 84 
Committee (Sport and Health Sciences, University of Exeter). All subjects participated in 85 
local cycling competitions. Trained individuals were selected as it has been shown that 86 
endurance training influences pain tolerance (O’Leary et al. 2017). After being informed of 87 
the experimental procedures and associated risks, all participants completed a medical health 88 
questionnaire, which was checked by a medical doctor, to ensure it was safe to consume ACT 89 
prior to performing exhaustive exercise. The questionnaire incorporated questions pertaining 90 
to: known allergies to medications, current intake of medication and prior use of ACT as well 91 
as any history of illnesses, cigarette use, alcohol consumption, illegal drug use and chronic 92 
illnesses (personal and family history). None of the participants had a history of motor and/or 93 
neurological disorders or frequent chronic ingestion of pain relief medication (i.e. ACT, non-94 
steroidal anti-inflammatory medication etc.). Participants were also advised to avoid 95 
ingestion of pain relief medication over the duration of the study and were provided with a 96 
list of prohibited medication(s). Participants were instructed to arrive at the laboratory in a 97 
 
 
rested and fully hydrated state, at least 3 h post-prandial, and to avoid strenuous exercise, and 98 
consumption of caffeine and alcohol in the 24 h prior to each testing session. 99 
 100 
Experimental Design 101 
Participants visited the laboratory on 5 occasions over a 5- to 6-week period with all tests 102 
conducted at a similar time of day (± 90 min). All tests were conducted on an electronically 103 
braked cycle ergometer (Lode Excalibur Sport, Groningen, Netherlands). On the first 104 
laboratory visit, participants performed a ramp-incremental cycling test for the determination 105 
of the linear factor (as described below), gas exchange threshold (GET), peak aerobic power 106 
output and the peak oxygen uptake (V̇O2peak). During this initial laboratory visit, the seat and 107 
handlebar positions were adjusted for comfort and replicated for all tests. The second and 108 
third laboratory visits were used to familiarise participants to the measurements and 109 
experimental protocol as described below. During these visits (i.e. visits 2-3), participants 110 
completed a 3-min all-out cycling test to ensure the coefficient of variation for work done and 111 
CP between visits was <1% and that the criteria to ensure a valid test were fulfilled (Jones et 112 
al. 2010). For each 3-min test, achievement of V̇O2peak (>95%), as verified by the V̇O2peak 113 
achieved during the ramp incremental ramp tests, was an obligatory criterion for a valid test. 114 
In the one instance where these criteria were not fulfilled, the participant completed a further 115 
familiarisation trial prior to commencing the experimental trials. During these sessions, the 116 
settings and placement of EMG and peripheral nerve stimulation electrodes were recorded for 117 
each subject as a reference for electrode placement in subsequent experimental trials (see 118 
below for further details). These trials were not included in the subsequent data analysis. 119 
Participants then performed the fatiguing protocol under two experimental conditions: 120 
placebo (PL) and ACT. Experimental sessions were separated by 3-7 days.  121 
 122 
 
 
Experimental protocol 123 
All trials (visits 1-5) started with a standardised warm-up routine (10 min at 100-150 W, 124 
corresponding to <90% GET, followed by 5 min of passive rest) and testing of the optimal 125 
EMG electrode (for recording muscle activation), anode and cathode placement and 126 
stimulation intensity for peripheral nerve stimulation. Single peripheral nerve stimulation 127 
pulses were manually triggered at rest to determine the characteristics of the M-wave 128 
response to supra-maximal nerve stimulation. Neuromuscular function was assessed pre-, 129 
during- and post-trial (<10 s) as described below.   130 
 131 
The experimental protocol comprised a 3-min period of unloaded pedalling at the 132 
participant’s preferred cadence, followed by a 3-min all-out sprint, 60 min following 133 
ingestion of either PL (1 g maltodextrin) or 1 g ACT (visits 4-5). This timing was selected to 134 
coincide with the attainment of the peak plasma [ACT] concentration (Anderson et al. 2008). 135 
The placebo was made from dextrose powder inserted into gelatine capsules designed to have 136 
an identical appearance and weight to ACT capsules but without the analgesic and antipyretic 137 
effects. The order of trials for visits 4 and 5 were administered in a double-blind, randomised 138 
fashion using a counter-balanced cross-over experimental design. The 3-min all-out cycling 139 
protocol used in this study replicated the procedures described previously by Vanhatalo et al. 140 
(2007, 2008). The fixed resistance for the all-out sprint was set using the linear mode of the 141 
ergometer such that on reaching their preferred cadence, the participants would achieve a 142 
power output equivalent to 50% of the difference between GET and V̇O2peak (linear factor = 143 
50%∆ power output/preferred cadence2).  144 
 145 
Measurements 146 
Breath-by-breath pulmonary gas exchange 147 
 
 
Throughout all laboratory tests, participants wore a mask connected to an impeller turbine 148 
transducer assembly (Cortex Metalyzer, Cortex, Leipzig, Germany). Inspired and expired gas 149 
volume and concentration signals were continuously sampled at 100 Hz. The analyser was 150 
calibrated before each test with gases of known concentration (O2 15%, CO2 4.5%), and a 151 
calibration syringe of known volume (3-L; Hans Rudolph, KS).  152 
 153 
Electromyography  154 
Neuromuscular function was assessed pre-, during- and immediately post each of the trials. 155 
Pre- and post-trial neuromuscular function was tested with the participant cycling at 80 RPM 156 
with a low resistance (20 W) as described below. Surface EMG activity was measured from 157 
m. vastus lateralis, m. vastus medialis, m. rectus femoris and m. biceps femoris muscles of the 158 
right leg to continuously record muscle activity during exercise using active bipolar bar 159 
electrodes with a single differential configuration (DE2.1, DelSys Inc, Boston, MA, USA). 160 
Bipolar electrodes were positioned over the muscle belly parallel to the longitudinal axis of 161 
each muscle (SENIAM guidelines). The placement of electrodes was considered optimal on 162 
achieving the largest and most reproducible M-wave signal from the m.vastus lateralis and 163 
m.vastus medialis whilst noting minimal activity in the m.bicep femoris.  Placement of 164 
electrodes was optimised during each laboratory visit. Double-sided adhesive tape and a 165 
hypoallergenic medical tape were used to ensure the EMG sensor stability for recording 166 
electrodes. The skin area underneath each EMG electrode was shaved, then exfoliated and 167 
cleaned with alcohol to minimise the skin impedance. The EMG signal was pre-amplified 168 
(1000 x), band-pass filtered (20–450 Hz, Bagnoli-8, DelSys Inc, Boston, MA, USA), and 169 
then transferred to a computer with a sampling frequency of 2 kHz. EMG data were recorded 170 
continuously and digitised synchronously with 16 bit resolution via an A/D converter (±5 V 171 
range, CED 1401 power, Cambridge, UK). EMG was average rectified using the root mean 172 
 
 
square method (EMGRMS). EMGRMS throughout the trial was then normalised to the EMG 173 
signal during the first 30 s of the 3-min test to provide a percentage of the maximal signal. 174 
Finally, EMGRMS was normalised to the local (closest) standardised M-wave amplitude and 175 
presented as a percentage of the maximal signal. In addition, M-wave amplitude was 176 
normalised by pre-exercise, resting values, and presented as a percentage. This method of 177 
normalizing the EMG trace to the M-wave may enable a more accurate assessment of 178 
changes in muscle activation that are likely occurring upstream of the neuromuscular junction 179 
(i.e. spinal and/or supraspinal in origin). The ground electrode was placed over the patella of 180 
the right leg.  181 
 182 
Peripheral Nerve Stimulation 183 
Electrical stimulation was applied using a constant current stimulator (Digitimer Stimulator 184 
DS7AH, Digitimer, UK). Initially, the crank angle at which peripheral nerve stimulation was 185 
to be delivered during the trials was determined for each subject as described by Black et al. 186 
(2017) and as performed by Sidhu et al. (2012). Stimulations were delivered at the identified 187 
crank angle specific to each trial (62 ± 7° relative to full knee extension, 180°) to align with 188 
maximal EMGRMS amplitude. A custom written sequencer script triggered 3 single 189 
stimulations, independently, with at least 1 and up to 10 pedal revolutions between stimuli. 190 
During the 3-min cycling test, these stimulations were delivered every 30 s. M-waves were 191 
elicited in m.vastus lateralis and m.vastus medialis by supramaximal percutaneous electrical 192 
stimulation of the femoral nerve (200 µs duration), approximately 3–5 cm below the inguinal 193 
ligament in the femoral triangle. The cathode was systematically moved vertically and 194 
horizontally and the amplitude of the muscle action potential (i.e. M-wave) was monitored to 195 
identify the optimal position of the cathode for attaining maximal peak-to-peak M-wave 196 
(Mmax) amplitude. To determine the stimulation intensity, single stimuli were delivered in 20 197 
 
 
mA step-wise increments from 100 mA until a plateau (i.e. Mmax) in the M-wave was 198 
observed. A supramaximal pulse of 130% Mmax current (Burke, 2002; Goodall et al. 2010; 199 
Neyroud et al. 2014) was applied during the exercise tests (mean stimulation intensity: 251 ± 200 
48 mA). The procedures for optimal electrode placement and stimulation intensity were 201 
completed during each laboratory visit (visits 2-5).  202 
 203 
Data Analysis 204 
Data were analysed using a custom written script developed in Spike2 software (CED, 205 
Cambridge, UK). CP was estimated as the mean power output over the final 30 s of the test, 206 
and the Wʹ was estimated as the work done above the CP (Vanhatalo et al. 2007, 2008). Peak 207 
V̇O2 was determined as the highest 15-s interval (i.e. V̇O2peak). Total work was calculated as 208 
the area under the power-time curve. Peak power output attained in the 3-min test was 209 
defined as the maximal 1-s interval. The changes in power output, MMax and EMGRMS, were 210 
used to quantify neuromuscular fatigue development and changes in muscle activation. All 211 
neuromuscular parameters and power output were averaged across the protocol into 6 × 30-s 212 
bin averages. Estimates of CP and Wˈ were also used to predict the time taken to complete a 213 
range of total work done (W) targets (50, 75, 100, 125, 150, 175, 200, 225, 250, 500, 750, 214 
1000 kJ) as previously described (Kelly et al. 2013). 215 
 216 
Tlim = (W-Wʹ) / CP                                     (equation 1) 217 
 218 
Statistics 219 
Paired-samples t-tests were used to compare the CP, Wʹ, total work done and 220 
cardiorespiratory responses between ACT and PL conditions. In addition, paired samples t-221 
tests were used to assess parameters of neuromuscular function at task end between trials (i.e. 222 
 
 
Mmax and EMGRMS). The profiles of power output, M-wave amplitude and EMGRMS before, 223 
during and after the 3-min test were analysed using two-way ANOVAs (time × condition) 224 
with repeated measures (using 30 s averages; i.e. 6 time points) between PL and ACT. A two-225 
way repeated-measures ANOVA was also used to assess differences in predicted 226 
performance times. Where the ANOVA revealed a significant interaction effect, post-hoc 227 
comparisons were completed using a Bonferroni correction. A Pearson’s product moment 228 
correlation coefficient was used to determine the relationship between the change in EMG 229 
amplitude and the change in power production between conditions. A one-way ANOVA was 230 
used to assess differences in V̇O2peak obtained during the incremental ramp test and both 3-231 
min trials (PL and ACT). To assess the possibility of an order effect of trials, a paired 232 
samples t-test was conducted on total work done for visits 4 and 5. For calculation of effect 233 
size, partial eta squared (η2) was used for omnibus tests. Cohen's d was used to calculate the 234 
effect size for paired t-tests and post-hoc comparisons. All statistical tests were performed 235 
both on % change and raw data. Where sphericity was violated, a Greenhouse Geisser 236 
correction factor was used. For all tests, results were considered statistically significant when 237 
P<0.05. Data are presented as mean ± SD, unless otherwise indicated. All statistical analyses 238 
were conducted using IBM SPSS Statistics version 24. 239 
 240 
RESULTS 241 
Mean V̇O2peak measured in the ramp incremental test was 4.50 ± 0.41 L·min−1 (61 ± 6 242 
ml·kg−1·min−1) and the peak aerobic power output was 393 ± 29 W. The GET occurred at 243 
1.98 ± 0.26 L·min−1 and 152 ± 22 W. The V̇O2peak achieved during the 3-min test following 244 
PL (4.51 ± 0.59 L·min−1, 60 ± 7 ml·kg−1·min−1) and ACT ingestion (4.53 ± 0.57 L·min−1, 61 245 
± 8 ml·kg−1·min−1) were not significantly different to the values achieved during the ramp 246 
incremental test (P=0.77).  247 
 
 
 248 
3-min all-out cycling test 249 
The V̇O2 profile during the 3-min test for PL and ACT conditions is shown in figure 1 (panel 250 
A). In addition, the mean power output profile for all participants (and differences in CP) 251 
during the 3-min all-out cycling test is shown in figure 1 (panel B) for the PL and ACT 252 
conditions. Panel C represents changes to power output throughout the duration of the 3-min 253 
test in all trials and is provided in 30-s averages. During the PL trial, power output declined 254 
from 820 ± 139 W during the first 5 s of the test to 288 ± 31 W during the last 30 s of the 3-255 
min test (P<0.0001, η2=0.99; table 1). However, during the ACT trial, power output declined 256 
from 838 ± 127 W during the first 5 s of the test to 297 ± 32 W during the final 30 s of the 257 
test (table 1). There was a significant interaction effect (time × condition; P=0.04, η2=0.26) 258 
with the mean power output in the 3-min cycling test being greater in ACT (368 ± 36 W) 259 
compared to PL (363 ± 36 W, P=0.007, d=0.13). CP (ACT: 297 ± 32 W vs. PL: 288 ± 31 W, 260 
P<0.0001, d=0.28) and total work done (ACT: 66.4 ± 6.5 kJ vs. 65.4 ± 6.4 kJ; P=0.03, 261 
d=0.15) was higher with ACT compared to PL (table 1; figure 2). However, there was no 262 
difference in peak power output (ACT: 838 ± 127 W vs. PL: 820 ± 139 W, P=0.10, d=0.16) 263 
or Wʹ (ACT: 13.1 ± 2.9 vs. PL: 13.6 ± 2.4 kJ; P=0.19, d=0.20) during the 3-min cycling test 264 
between conditions. No order effect was observed between visit 4 and visit 5 for total work 265 
done (Visit 4: 65.8 ± 6.5 kJ vs. Visit 5: 66.0 ± 6.4 kJ; P=0.75, d=0.03). 266 
 267 
When the CP and Wʹ were combined to predict the time required to complete fixed work 268 
targets between 50 and 1000 kJ, using equation 1, the ANOVA revealed a main effect by 269 
condition (P<0.0001, η2=0.56) and an interaction effect (P<0.0001, η2=0.86, table 2). Post-270 
hoc analysis revealed that the performance times were lower in the ACT condition compared 271 
 
 
with the PL condition for all time-trials with the exception of the two shortest (i.e. 50 and 75 272 
kJ), with the improvement ranging from 1.1% (100 kJ) to 3.0% (1000 kJ). 273 
 274 
Neuromuscular Function 275 
From pre to post exercise, there was a main effect for time on M-wave amplitude in the 276 
m.vastus lateralis (P=0.003, η2=0.29, figure 3), which declined as the protocol progressed. 277 
However, there was no main effect by condition (P=0.66, η2=0.01) or time × condition 278 
interaction effect (P=0.70, η2=0.03). EMGRMS in the m.vastus lateralis decreased from 94 ± 279 
4% over the first 30 s to 54 ± 17% over the final 30 s of the 3-min all-out test in the PL trial 280 
(P<0.0001, η2=0.50; figure 4). However, this decline in EMGRMS was attenuated following 281 
ACT ingestion (from 92 ± 5 over the first 30 s to 72 ± 18% over the final 30 s of the 3-min 282 
all-out test), with there being a time × condition interaction effect (P=0.04, η2=0.23). Post-283 
hoc analysis revealed EMGRMS was elevated at 150 s (P=0.02, d=0.84) and 180 s (P=0.001, 284 
d=1.31) in ACT compared to PL (figure 4). There was a significant positive correlation 285 
between the change in EMG amplitude and the change in power production over the last 30 s 286 
of exercise between conditions (r=0.88, P=0.04, figure 5). 287 
 288 
DISCUSSION 289 
Consistent with our hypotheses, the principal original findings of this study were that acute 290 
ACT ingestion enhanced total work done and CP, and attenuated the decline in EMG 291 
amplitude, in trained individuals during a 3-min all-out cycling test. The ACT-induced 292 
increase in CP was predicted to translate into a 1-3% reduction in the time required to 293 
complete a range of target work cycling trials (100-1000 kJ). The results of this study provide 294 
some insight into the mechanisms by which ACT ingestion is ergogenic during large muscle 295 
 
 
mass exercise and suggest that enhanced performance following ACT ingestion is 296 
attributable, at least in part, to increases in CP and muscle activation.   297 
 298 
Power-duration relationship 299 
Our finding of an increase in total work done following acute ACT ingestion in the 3-min all-300 
out cycling test is consistent with previous observations of enhanced exercise performance 301 
following acute ACT ingestion of similar doses (1-1.5 g; Foster et al. 2014; Mauger et al. 302 
2010, Morgan et al. 2018). In the present study, neuromuscular fatigue development was 303 
assessed during the completion of a 3-min all-out cycling test to offer insight into the 304 
potential underlying mechanisms for the ergogenic effects of ACT ingestion. Consistent with 305 
our previous finding of a 4% increase in critical torque when utilising a single-limb knee-306 
extension model (Morgan et al. 2018), CP achieved during a 3-min all-out cycling test was 307 
improved by ~3% following the acute ingestion of ACT in the present study. Moreover, and 308 
consistent with our previous findings (Morgan et al. 2018), W′ was not altered following 309 
ACT ingestion in the current study.  310 
 311 
The potential practical significance of the 3% improvement in CP becomes clear when 312 
applied to an exercise performance scenario. An important practical application of the CP is 313 
that this parameter, in conjunction with W′, can be used to robustly predict cycling TT 314 
performance (Black et al. 2014, 2017; Burnley et al. 2012; Chidnok et al. 2013; Florence & 315 
Weir, 1997; Skiba et al. 2012; Smith et al. 1999). Accordingly, the influence of a given 316 
intervention on CP and W′ can be used to predict the effect that that intervention might have 317 
on endurance exercise performance. For example, although Kelly et al. (2013) reported no 318 
statistically significant increase in either CP (+1.4%) or W′ (+8.4%) following dietary nitrate 319 
supplementation, when the combined effect on these parameters was integrated, an 320 
 
 
improvement of 2-3% in cycling time-trial performance was predicted. Similarly, in the 321 
current study, endurance performance was predicted to be improved by ~1-3% following 322 
acute ACT ingestion in the work trial simulations (~5-60 min). Since this magnitude of 323 
performance enhancement following acute ACT ingestion exceeds 0.6%, which is suggested 324 
to be the smallest ‘worthwhile’ improvement in road TT cycling (Paton & Hopkins, 2006), 325 
our results suggest that acute ACT ingestion may enable a practically meaningful 326 
improvement in endurance exercise performance. It should also be noted that, although we 327 
did not directly assess the effect of acute ACT ingestion on cycling TT performance in the 328 
current study, the predicted 1-3% is similar to the empirically demonstrated 1.8% 329 
improvement in 10-mile cycling TT performance reported previously (Mauger et al. 2010). 330 
 331 
Interestingly, improvements in exercise performance with acute ACT ingestion have been 332 
reported in trained participants in both the current study and in previous studies (Mauger et 333 
al. 2010) despite evidence that endurance training increases pain tolerance (Jones et al. 2014; 334 
O’Leary et al. 2017) such that trained individuals are more likely to have a greater tolerance 335 
to pain (Janal et al. 1994; Tesarz et al. 2013). However, it should be stressed that, although 336 
the current and previous studies support an ergogenic effect of acute ACT consumption 337 
(Foster et al. 2014; Mauger et al. 2010, 2014; Morgan et al. 2018), regular ACT use, or 338 
exceeding a single dose of 1 g, is not recommended given the hepatotoxicity of ACT 339 
(Graham et al. 2013).  340 
          341 
Neuromuscular function 342 
In addition to influencing the degree of muscle metabolic perturbation and the trajectory of 343 
the V̇O2 slow component during exercise (Jones et al. 2008, 2010; Poole et al. 1988; 344 
Vanhatalo et al. 2011), CP is linked to muscle activation characteristics during exercise, as 345 
 
 
inferred from EMG responses, and is a critical threshold for neuromuscular fatigue 346 
development (Burnley et al. 2012). Indeed, concomitant with our observation of an increased 347 
CP in the current study, the decline in EMG amplitude during the 3-min all-out test was 348 
attenuated in ACT compared to PL. These findings are strikingly similar to our recent study, 349 
which reported a blunted decline in the EMG amplitude and an increased critical torque 350 
during a 5-min maximal intermittent single-legged knee extension exercise task (Morgan et 351 
al. 2018). Together, these results suggest that improved maintenance of muscle activation 352 
contributes to the elevated CP and total work done following ACT ingestion. However, the 353 
blunting of neuromuscular fatigue development following ACT ingestion was not 354 
accompanied by improvements in peripheral muscle excitability, as inferred from 355 
measurements of M-wave amplitude between the ACT and PL trials, suggesting that this 356 
alteration occurred due to mechanisms upstream of the neuromuscular junction.  357 
 358 
Our results support the notion that the ergogenic effect of ACT is principally mediated 359 
centrally (Anderson, 2008; Graham et al. 2013; Smith, 2009; Toussaint et al. 2010). 360 
However, while we are not aware of any evidence to suggest that ACT might influence 361 
peripheral muscle excitability (Mauger & Hopker, 2013), or that interventions aimed at 362 
reducing inflammation improve performance during whole body exercise (i.e. Cleak, & 363 
Eston. 1992; Da Silva et al. 2015; Nosaka & Clarkson, 1996; Tokmakdis et al. 2003), we 364 
cannot exclude that peripheral factors that were not assessed in the current study, such as 365 
inflammation and/or alterations to muscle metabolism, may have contributed to the ergogenic 366 
effect of ACT. Moreover, due to the nature of cycling exercise, it is technically challenging to 367 
directly test cortical alterations via changes to voluntary activation using the interpolated 368 
twitch technique (Doyle-Baker et al. 2017).  369 
 370 
 
 
Whilst we have previously investigated the contribution of central and peripheral factors to 371 
the improved performance following ACT ingestion in a small muscle mass model (Morgan 372 
et al. 2018), the mechanisms underpinning fatigue development, and therefore ACT’s 373 
potential ergogenic effect, could differ for large muscle mass exercise (Rossman et al. 2012, 374 
2014).  We observed a strong correlation between the change in end-exercise EMGRMS and 375 
the change in power output (i.e. CP) within the last 30 s of the 3-min cycling test (r=0.88) 376 
following ACT ingestion compared to placebo. However, the change in EMGRMS was much 377 
larger than the change in CP. Although the mechanisms for this effect remain to be defined, 378 
this observation is in agreement, with Felippe et al. (2018).  Specifically, these authors 379 
reported that, compared to placebo, caffeine ingestion increased mean power output by ~4% 380 
during a 4-km cycling test, resulting in a 2% reduction in time to complete the 4-km distance, 381 
alongside a ~17% increase in muscle recruitment (as inferred by EMG). 382 
 383 
It is possible that, through lowering pain sensation (Foster et al. 2014; Mauger et al. 2010), 384 
ACT might have permitted the development of, and/or tolerance to, a greater degree of 385 
intramuscular metabolic perturbation beyond that required to evoke a ‘critical’ threshold of 386 
peripheral fatigue, thereby permitting improved exercise performance (Blain et al. 2016). 387 
Alternatively, since the effects of ACT are believed to be largely centrally mediated 388 
(Anderson, 2008; Graham et al. 2013; Smith, 2009; Toussaint et al. 2010), it is possible that 389 
ACT ingestion attenuated the development of central fatigue. A blunting in central fatigue 390 
development following ACT ingestion would be expected to permit enhanced central motor 391 
output, possibly through a reduction in inhibitory feedback via cyclooxygenase inhibition and 392 
a resultant decline in the synthesis of prostaglandins. 393 
 394 
 
 
The higher EMGRMS during the latter stages of the 3-min all-out cycling test observed 395 
following ACT ingestion may have been a consequence of enhanced corticospinal 396 
excitability (Mauger & Hopker, 2013). Greater corticospinal excitability following ACT 397 
ingestion, as inferred from a greater motor-evoked potential in the study of Mauger & Hopker 398 
(2013), may be linked to enhanced firing of motor units, and increased spinal excitability, as 399 
has been reported with caffeine consumption (i.e. Kalmar & Cafarelli, 2004; Walton et al. 400 
2003). Together, these effects on motor cortical and/or spinal excitability may explain the 401 
enhanced muscle activation and the subsequent greater amount of work performed with ACT 402 
ingestion in the current study. However, since cortical and peripheral contributions to fatigue 403 
development were not directly tested in this study, further research is required to resolve the 404 
underlying mechanisms for the ACT-mediated enhancement in muscle activation and 405 
performance during maximal exercise.  406 
 407 
In conclusion, acute ACT ingestion increased total work done during a 3-min all-out cycling 408 
test in agreement with earlier reports of an ergogenic effect of ACT ingestion on cycling 409 
performance. The improved performance in the 3-min all-out test was accompanied by an 410 
increase in CP and better preservation of the EMG amplitude during the latter stages of the 411 
protocol. When the ACT-induced increase in CP was used to predict the effects of acute ACT 412 
ingestion on cycling performance, the estimated 1-3% improvement was in line with previous 413 
experimental observations. Therefore, our results extend previous reports by revealing that 414 
ACT ingestion improves performance concomitant with enhanced CP and muscle activation 415 
during a 3-min all-out cycling test.  These observations provide insight into the ergogenic 416 
effect of ACT ingestion during large muscle mass exercise.  417 
 
 
 
Conflict of interest 418 
The authors report no conflict of interest in the publication of this research 419 
 420 
Acknowledgements 421 
This research was not sponsored by any funding body external to University of Exeter. The 422 
authors report no conflict of interest in the publication of this research. The results are 423 
presented clearly, honestly, and without fabrication, falsification or inappropriate data 424 
manipulation. 425 
 426 
Author contribution 427 
P.T. Morgan, A. Vanhatalo, A.M. Jones and S.J. Bailey conceived and designed the research. 428 
P.T. Morgan conducted all experiments. J.L. Bowtell provided assistance with pilot testing 429 
prior to experimental data collection as well supporting data analysis. P.T. Morgan wrote the 430 
manuscript. J.L. Bowtell, A. Vanhatalo, A.M. Jones and S.J. Bailey helped supervise the 431 
project throughout. All authors contributed to the interpretation of results and read, edited and 432 
approved the manuscript.  433 
 
 
References 434 
Anderson, B.J. 2008. Paracetamol (Acetaminophen): mechanisms of action. Paediatr 435 
Anaesth. 18: 915-921.  436 
 437 
Astokorki, A.H.Y., and Mauger, A.R. 2017a. Tolerance of exercise-induced pain at a fixed 438 
rating of perceived exertion predicts time trial cycling performance. Scand. J. Med. Sci. 439 
Sports. 27(3): 309–317. 440 
 441 
Astokorki, A.H.Y., and Mauger, A.R. 2017b. Transcutaneous electrical nerve stimulation 442 
reduces exercise-induced perceived pain and improves endurance exercise performance. Eur. 443 
J. Appl. Physiol. 117(3): 483–492. 444 
 445 
Black, M.I., Durant, J., Jones, A.M., and Vanhatalo, A. 2014. Critical power derived from a 3 446 
min all-out test predicts 16.1-km road time-trial performance. Eur. J. Sport Sci. 14: 217-223.  447 
 448 
Black, M.I., Jones, A.M., Blackwell, J.R., Bailey, S.J., Wylie, L.J., McDonagh, S.T.J., 449 
Thompson, C., Kelly, J., Sumners, P., Mileva, K.N., et al. 2017. Muscle metabolic and 450 
neuromuscular determinants of fatigue during cycling in different exercise intensity domains. 451 
J. Appl. Physiol. 122(3): 446–459. 452 
 453 
Blain, G.M., Mangum, T.S., Sidhu, S.K., Weavil, J.C., Hureau, T.J., Jessop, J.E., Bledsoe, 454 
A.D., Richardson, R.S., and Amann, M. 2016. Group III/IV muscle afferents limit the 455 
intramuscular metabolic perturbation during whole body exercise in humans. J. Physiol. 456 
594(18): 5303-5315.  457 
 458 
 
 
Burke, D. 2002. Effects of activity on axonal excitability: implications for motor control 459 
studies. Adv. Exp. Med. Biol. 508: 33-37. 460 
 461 
Burnley, M., Vanhatalo, A., and Jones, A.M. 2012. Distinct profiles of neuromuscular fatigue 462 
during muscle contractions below and above the critical torque in humans. J. Appl. Physiol. 463 
113: 215-223.  464 
 465 
Chidnok, W., Fulford, J., Bailey, S.J., DiMenna, F.J., Skiba, P.F., Vanhatalo, A., and Jones, 466 
A.M. 2013. Muscle metabolic determinants of exercise tolerance following exhaustion: 467 
relationship to the “critical power.” J. Appl. Physiol. 115(2): 243–250.  468 
 469 
Cleak, M.J., and Eston, R.G. 1992. Muscle soreness, swelling, stiffness and strength loss after 470 
intense eccentric exercise. Br. J. Sports Med. 26: 267–272. 471 
 472 
Da Silva, E., Pinto, R.S., Cadore, E.L., and Kruel, L.F. 2015. Nonsteroidal anti-inflammatory 473 
drug use and endurance during running in male long-distance runners. J. Athl. Train. 50: 474 
295–302. 475 
 476 
Enoka, R.M., and Duchateau, J. 2008. Muscle fatigue: what, why and how it influences 477 
muscle function. J. Physiol. 586: 11-23.  478 
 479 
Felippe, L.C., Ferreira, G.A., Learsi, S.K., Boari, D., Bertuzzi, R., and Lima-Silva, A.E. 480 
2018. Caffeine increases both total work performed above critical power and peripheral 481 
fatigue during a 4-km cycling time trial. J. Appl. Physiol. 24(6): 1491-1501. 482 
 483 
 
 
Florence, S., and Weir, J.P. 1997. Relationship of critical velocity to marathon running 484 
performance. Eur. J. Appl. Physiol. Occ. Physiol. 75(3): 274–8.  485 
 486 
Foster, J., Taylor, L., Chrismas, B.C., Watkins, S.L., and Mauger, A.R. 2014. The influence 487 
of acetaminophen on repeated sprint cycling performance. Eur. J. Appl. Physiol. 114: 41-48. 488 
 489 
Goodall, S., Ross, E.Z., and Romer, L.M. 2010. Effect of graded hypoxia on supraspinal 490 
contributions to fatigue with unilateral knee-extensor contractions. J. Appl. Physiol. 109(6): 491 
1842-51. 492 
 493 
Graham, G.G., Davies, M.J., Day, R.O., Mohamudally, A., and Scott, K.F. 2013. The modern 494 
pharmacology of paracetamol: therapeutic actions, mechanism of action, metabolism, toxicity 495 
and recent pharmacological findings. Inflammopharmacology, 21: 201-232.  496 
 497 
Hureau, T.J., Romer, L.M., and Amann, M. 2016. The 'sensory tolerance limit': A 498 
hypothetical construct determining exercise performance? Eur. J. Sport Sci. 7: 1-12.  499 
 500 
Janal, M.N., Glusman, M., Kuhl, J.P., and Clark, W.C. 1994. Are runners stoical? An 501 
examination of pain sensitivity in habitual runners and normally active controls. Pain, 58(1): 502 
109–116.  503 
 504 
Jones, A.M., Vanhatalo, A., Burnley, M., Morton, R.H., and Poole, D.C. 2010. Critical 505 
power: Implications for determination of VO2max and exercise tolerance. Med. Sci. Sports 506 
Exerc. 42(10): 1876–1890.  507 
 508 
 
 
Jones, A.M., Wilkerson, D.P., DiMenna, F., Fulford, J., and Poole, D.C. 2008. Muscle 509 
metabolic responses to exercise above and below the "critical power" assessed using 31P-510 
MRS. Am. J. Physiol. Regul. Integr. Comp. Physiol. 294: 585-593. 511 
 512 
Kalmar, J.M., and Cafarelli, E. 2004. “Central Fatigue and Transcranial Magnetic 513 
Stimulation: Effect of Caffeine and the Confound of Peripheral Transmission Failure.” J. 514 
Neuros Methods, 138(1–2): 15–26.  515 
 516 
Kelly, J., Vanhatalo, A., Wilkerson, D.P., Wylie, L.J., and Jones, A.M. 2013. Effects of 517 
nitrate on the power-duration relationship for severe-intensity exercise. Med. Sci. Sports 518 
Exerc. 45(9): 1798–1806. 519 
 520 
Mauger, A.R., and Hopker, J.G. 2013. The effect of acetaminophen ingestion on cortico-521 
spinal excitability. Can. J. Physiol. Pharmacol. 91: 187–189.  522 
 523 
Mauger, A.R., Jones, A.M., and Williams, C.A. 2010. Influence of acetaminophen on 524 
performance during time trial cycling. J. Appl. Physiol. 108: 98-104.  525 
 526 
Mauger, A.R., Taylor, L., Harding, C., Wright, B., Foster, J., and Castle, P.C. 2014. Acute 527 
acetaminophen (paracetamol) ingestion improves time to exhaustion during exercise in the 528 
heat. Exp. Physiol. 99: 164–171. 529 
 530 
Morgan, P.T., Bowtell, J.L., Vanhatalo, A., Jones, A.M., and Bailey, S.J. 2018. Acute 531 
acetaminophen ingestion improves performance and muscle activation during maximal 532 
intermittent knee extensor exercise. Eur. J. Appl. Physiol. 118(3): 595–605.  533 
 
 
 534 
Neyroud, D., Vallotton, A., Millet, G.Y., Kayser, B., and Place, N. 2014. The effect of 535 
muscle fatigue on stimulus intensity requirements for central and peripheral fatigue 536 
quantification. Eur. J. Appl. Physiol. 114(1): 205-15.  537 
 538 
Nosaka, K., and Clarkson, P.M. 1996. Changes in indicators of inflammation after eccentric 539 
exercise of the elbow flexors. Med. Sci. Sports Exerc. 28: 953–961. 540 
 541 
O’Connor, P.J., Motl, R.W., Broglio, S.P., and Ely, M.R. 2004. “Dose-Dependent Effect of 542 
Caffeine on Reducing Leg Muscle Pain during Cycling Exercise Is Unrelated to Systolic 543 
Blood Pressure.” Pain, 109(3): 291–98.  544 
 545 
O’Leary, T.J., Collett, J., Howells, K., and Morris, M.G. 2017. High but not moderate-546 
intensity endurance training increases pain tolerance: a randomised trial. Eur. J. Appl. 547 
Physiol. 117(11): 2201–2210. 548 
 549 
Paton, C.D., and Hopkins, W.G. 2006. Variation in performance of elite cyclists from race to 550 
race. Eur. J. Sport Sci. 6(1): 25–31. 551 
 552 
Pickering, G., Estève, V., Loriot, M.A., Eschalier, A., and Dubray, C. 2008. Acetaminophen 553 
reinforces descending inhibitory pain pathways. Clin. Pharmacol. Ther. 84: 47-51. 554 
 555 
Pickering, G., Loriot, M.A., Libert, F., Eschalier, A., Beaune, P., and Dubray, C. 2006. 556 
Analgesic effect of acetaminophen in humans: first evidence of a central serotonergic 557 
mechanism. Clin. Pharmacol. Ther. 79: 371-378. 558 
 
 
 559 
Poole, D.C., Burnley, M., Vanhatalo, A., Rossiter, H.B., and Jones, A.M. 2016. Critical 560 
power: An important fatigue threshold in exercise physiology. Med. Sci. Sports Exerc. 561 
48(11): 2320–2334. 562 
 563 
Poole, D.C., Ward, S.A., Gardner, G.W., and Whipp, B.J. 1988. Metabolic and respiratory 564 
profile of the upper limit for prolonged exercise in man. Erg. 31: 1265-79.  565 
 566 
Rossman, M.J., Garten, R.S., Venturelli, M., Amann, M., and Richardson, R.S. 2014. The 567 
role of active muscle mass in determining the magnitude of peripheral fatigue during 568 
dynamic exercise. Am. J. Physiol. Regul. Integr. Comp. Physiol. 306(12): 934–940. 569 
 570 
Rossman, M.J., Venturelli, M., Mcdaniel, J., Amann, M., and Richardson, R.S. 2012. Muscle 571 
mass and peripheral fatigue: A potential role for afferent feedback? Acta Physiologica, 572 
206(4): 242–250. 573 
 574 
Sidhu, S.K., Cresswell, A.G., and Carroll, T.J. 2012. Motor cortex excitability does not 575 
increase during sustained cycling exercise to volitional exhaustion. J. Appl. Physiol. 113(3): 576 
401–409. 577 
 578 
Skiba, P.F., Chidnok, W., Vanhatalo, A., and Jones, A. 2012. Modeling the expenditure and 579 
reconstitution of work capacity above critical power. Med. Sci. Sports Exerc. 44(8): 1526–580 
1532.  581 
 582 
 
 
Smith, H.S. 2009. Potential analgesic mechanisms of acetaminophen. Pain Physician, 12: 583 
269-80.  584 
 585 
Smith, J.C., Dangelmaier, B.S., and Hill, D.W. 1999. Critical power is related to cycling time 586 
trial performance. Int. J. Sports Med. 20: 374-378.  587 
 588 
Tesarz, J., Gerhardt, A., Schommer, K., Treede, R.D., and Eich, W. 2013. Alterations in 589 
endogenous pain modulation in endurance athletes: An experimental study using quantitative 590 
sensory testing and the cold-pressor task. Pain, 154(7): 1022–1029. 591 
 592 
Toussaint, K., Yang, X.C., Zielinski, M.A., Reigle, K.L., Sacavage, S.D., Nagar, S., and 593 
Raffa, R.B. 2010. What do we (not) know about how paracetamol (acetaminophen) works? J 594 
Clin Pharm. Ther. 35: 617-638.  595 
 596 
Vanhatalo, A., Black, M.I., DiMenna, F.J., Blackwell, J.R., Schmidt, J.F., Thompson, C., 597 
Wylie, L.J., Mohr, M., Bangsbo, J., Krustrup, P., et al. 2016. The mechanistic bases of the 598 
power–time relationship: muscle metabolic responses and relationships to muscle fibre type. 599 
J. Physiol. 594(15): 4407–4423.  600 
 601 
Vanhatalo, A., Doust, J.H., and Burnley, M. 2008. A 3 min all-out cycling test is sensitive to 602 
a change in critical power. Med. Sci. Sports Exerc. 40(9): 1693–1699.  603 
 604 
Vanhatalo, A., Doust, J.H., and Burnley, M. 2007. Determination of critical power using a 3-605 
min all-out cycling test. Med. Sci. Sports Exerc. 39(3): 548–555. 606 
 607 
 
 
Vanhatalo, A., Jones, A.M., and Burnley, M. 2011. Application of critical power in sport. Int. 608 
J. Sports Physiol. Perform. 6(1): 128–136. 609 
 610 
Walton, C., Kalmar, J., and Cafarelli, E. 2003. Caffeine increases spinal excitability in 611 
humans. Muscle Nerve, 28: 359–36612 
 
 
 
Figure captions 613 
Figure 1 614 
Group mean ± SE V̇O2 during acetaminophen (ACT, filled circles) and placebo (PL, clear 615 
circles) is presented in panel A. The dashed line represents the V̇O2peak attained in the 616 
incremental ramp test. Panel B illustrates the mean ± SE power output profile during the 3-617 
min maximal cycling protocol for placebo (clear circles) and acetaminophen (filled circles) 618 
trials derived from 15 s averages.  Note that after attainment of peak power output a few 619 
seconds into the test, power output falls over the first ~90-120 s before reaching stable values 620 
(the end-test power output; i.e. CP). CP is significantly elevated in the last 30 s of the ACT 621 
condition. Significant changes to power output over time (derived from 30 s averages) 622 
throughout the 3-min cycling test for both ACT and PL conditions are shown in panel C. 623 
*Significantly different from PL (i.e. main effect of condition); asignificantly different from 624 
30 s; bsignificantly different from 60 s; csignificantly different from 90 s; dsignificantly 625 
different from 120 s (main effect of time, P<0.05). 626 
 627 
Figure 2 628 
Group mean total work done in the placebo (PL) and acetaminophen (ACT) conditions are 629 
shown in the open and closed bars, respectively (Panel A). Individual responses in the PL and 630 
ACT conditions are shown by the open circles and linked with dashed lines. *Significantly 631 
different from PL (P<0.05). Panel B represents the group mean critical power (CP) in the PL 632 
and ACT conditions in the open and closed bars, respectively. Individual responses in the PL 633 
and ACT conditions are shown by the open circles and linked with dashed lines. 634 
 635 
 
 
 
Figure 3 636 
M-wave amplitude responses in the m.vastus lateralis during the 3-min cycling test for 637 
placebo (clear circles) and acetaminophen (filled circles) trials.  Mean ± SE M-wave 638 
responses are presented in panel A with the M-wave response from a representative 639 
individual presented in panel B, for PL (grey line) and ACT (black line), for the first 30 and 640 
final 30 s, respectively of the 3-min protocol. asignificantly different from baseline; 641 
bsignificantly different from 30 s (P<0.05). 642 
 643 
Figure 4 644 
Surface electromyography (EMG) responses (expressed relative to M-wave amplitude) in the 645 
m.vastus lateralis during the 3-min cycling test for placebo (clear circles) and acetaminophen 646 
(filled circles) trials.  Mean ± SE EMG responses are presented in panel A with the EMG 647 
response from a representative individual presented in panel B, for PL (grey line) and ACT 648 
(black line), for the first 30 and final 30 s, respectively of the 3-min protocol. *Significantly 649 
different from placebo; asignificantly different from 30 s; bsignificantly different from 60 s; 650 
csignificantly different from 90 s; dsignificantly different from 120 s; esignificantly different 651 
from 150 s (P<0.05). 652 
 653 
Figure 5 654 
Correlation between the change in electromyography amplitude (EMG, %) and the change in 655 
critical power (CP) between conditions (acetaminophen and placebo). The solid line 656 
represents the line of best fit. 657 
